TARA
vs
S&P 500
TARA
S&P 500
Over the past 12 months, TARA has underperformed S&P 500, delivering a return of +2% compared to the S&P 500's +14% growth.
Stocks Performance
TARA vs S&P 500
Performance Gap
TARA vs S&P 500
Performance By Year
TARA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Protara Therapeutics Inc
Glance View
Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 31 full-time employees. The company went IPO on 2014-10-22. The firm is focused on identifying therapies for the treatment of cancer and rare diseases. The firm's pipeline includes TARA-002 and IV Choline Chloride. The firm's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy, which is in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD).